Abstract 1666P
Background
Substance use and mental health disorders significantly contribute to disparities in cancer care, particularly in urban underserved areas like the South Bronx, characterized by a substantial Latinx and Black population. This study aimed to evaluate the influence of substance use and mental illness on cancer care among newly diagnosed patients at the Lincoln Cancer Center.
Methods
A retrospective analysis was conducted on newly diagnosed cancer patients treated between January and August 2022. Various aspects of their cancer care journey were assessed, including delays in diagnosis, treatment selection, compliance with care, incidence of unscheduled emergency department/inpatient visits, rates of follow-up loss, and mortality. Substance use and mental health disorders were evaluated through electronic health record reviews and structured telephone interviews. Statistical analysis was performed using descriptive statistics and the independent samples T-test in SPSS. This study was approved by the Institutional Review Board at our hospital.
Results
The study included 208 patients, with 106 (51%) having substance use disorders, 41 (19.1%) with mental health disorders and 31 (14.9%) having both. Among patients with mental health disorders, 34% received medication and 12% had regular psychiatric care. Patients with mental health disorders but no substance use, tended to be diagnosed at later cancer stages (50% vs 41.3% at stage 4). Patient with either mental health disorders or substance use disorder has delayed cancer diagnosis from initial suspicion date (64.09 days vs 46.71 days, p = 0.154) and higher non-compliance to clinic visits (20.9% vs 14.0%, p=0.015) and higher ED visit (1.67 vs 1.27, p = 0.71), admission rate (0.98 vs 0.57, p=0.232) and mortality compared to those without, showing odds ratios of 1.203 [95% CI 0.50-2.89] although statistically insignificant due to the small sample size.
Conclusions
Patients with either mental health disorders or substance use disorder exhibited more diagnostic delays, higher non-compliance with their cancer care journey, increased ED/inpatient visits, and mortality rates. Addressing both physical and mental health is crucial for narrowing cancer disparities in this vulnerable population.
Clinical trial identification
Editorial acknowledgement
Legal entity responsible for the study
The authors.
Funding
Has not received any funding.
Disclosure
All authors have declared no conflicts of interest.
Resources from the same session
1646P - A multicohort phase II trial of androgen deprivation therapy (ADT), docetaxel (DOCE) and nivolumab (NIVO) in patients (pts) with newly diagnosed metastatic hormone sensitive prostate cancer (mHSPC) enriched for inflamed tumours and DNA damage repair (DDR) alterations: Cohort 3 results
Presenter: Xiao Wei
Session: Poster session 11
1647P - Clinical validity of plasma DNA testing to identify BRCA-mutated (BRCA+) patients in the MAGNITUDE study
Presenter: Gerhardt Attard
Session: Poster session 11
1649P - Impact of concomitant medications on safety in patients with high-volume metastatic hormone-sensitive prostate cancer (mHSPC) receiving rezvilutamide (Rez) plus androgen-deprivation therapy (ADT): A post-hoc analysis of the randomized phase III CHART trial
Presenter: Dingwei Ye
Session: Poster session 11
1650P - Fuzuloparib plus abiraterone acetate and prednisone (AA-P) in patients (pts) with metastatic castration-resistant prostate cancer (mCRPC): A phase I study
Presenter: Tao Dai
Session: Poster session 11
1651P - Characteristics, tolerance and effectiveness of patients aged more or less than 75 years treated with [177Lu]Lu-PSMA-617 as part of France’s early access program
Presenter: David Tonnelet
Session: Poster session 11
1652P - SAABR: Single arm phase II study of androgen receptor pathway inhibitor (ARPI) + atezolizumab + GnRH analog (ADT) and stereotactic body radiotherapy (SBRT) to the prostate in men with de novo hormone-sensitive metastatic prostate cancer (mHSPC)
Presenter: Dana Rathkopf
Session: Poster session 11
1653P - Molecular and immunologic correlates of high PSMA/FOLH1 mRNA expression in prostate cancer (PC)
Presenter: Rana McKay
Session: Poster session 11
1654P - TAMARACK: Randomized Phase II trial of the B7-H3 targeting antibody drug conjugate (ADC) vobramitamab duocarmazine (vobra duo) in metastatic castration-resistant prostate cancer (mCRPC)
Presenter: Johann de Bono
Session: Poster session 11
1655P - Association of location of BRCA1/2 pathogenic variants with benefit from PARP-inhibitors in metastatic castration-resistant prostate cancers: Results from the PROGRESS study
Presenter: Lorena Incorvaia
Session: Poster session 11